Abstract: One aspect of this disclosure relates to presenting a user with a stimulus to elicit user interaction with a task on a computing platform associated with the user. The stimulus may be presented on the computing platform when a set of triggering criteria is satisfied. The stimulus includes a task for the user to complete. The stimulus prompts the user to complete the task. The task includes a set of task criteria for completion. Responsive to the user satisfying the set of task criteria, the user is presented with one or more options to modify the stimulus. The user may be continuously prompted by the stimulus until the set of task criteria is satisfied.

Abstract: A reflective optical data modulator includes a layer of optical material, a front partial optical reflector on a major surface of the layer of optical material, a back optical reflector, and at least two electrodes. The back optical reflector is at or near a portion of a second surface of the layer of optical material and faces the front partial optical reflector. The at least two, electrodes are located to enable application of a voltage across a portion of the layer of optical material. The layer of optical material has an optical absorption dependent on the voltage applied across the electrodes. The front partial optical reflector is an unburied layer structure.

Abstract: Optical transmitters, receivers, and transceivers implemented using a plurality of surface-coupled optical devices that can be manufactured on the same planar substrate and then post-processed to provide some of the devices with different respective partially transparent front mirrors compatible with and/or customized for different respective optical functions. When appropriately electrically biased and driven, different subsets of such devices can operate as lasers, optical modulators, optical amplifiers, and photodetectors, respectively. In this manner, an integrated array of such devices can be customized to provide the optical functions needed for the intended product. For example, an optical transmitter can be constructed using an integrated array that comprises three surface-coupled optical devices configured to operate as a laser, an optical modulator, and an optical amplifier, respectively.

Abstract: This disclosure provides an operation apparatus, an operation execution device and an operation execution method. The operation execution device includes: a controller, a memory and an operation apparatus; the memory is configured to store a preset single instruction set; the single instruction set includes a single instruction corresponding to a per-layer operation when the operation apparatus performs a multi-layer operation; each of the single instructions includes a module selecting parameter and a module operating parameter; the controller is configured to read a current single instruction corresponding to a current layer operation, and parse the module selecting parameter and the module operating parameter to determine a operation path; the operation apparatus is configured to be connected with the operation path, and perform operation on input data of the operation apparatus in the current layer operation by using the operation path, generate output data of the current layer operation.

Abstract: An anode active material for a lithium-ion battery with greatly reduced recharging time includes SiO particles, graphite particles, and a carbon coating layer. The graphite particles and SiO particles are processed to form spherical SiO/graphite composite particles. A layer of carbon coating is applied to the surface of the SiO/graphite composite particle and the resulting anode active material resembles a pomegranate structure.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.

Abstract: Embodiments of the present disclosure provide signal encoding and decoding methods and devices. The method includes: determining, a quantity k of subbands to be encoded, where i is a positive number, and k is a positive integer; selecting, according to quantized envelopes of all subbands, k subbands from all the subbands, or selecting k subbands from all subbands according to a psychoacoustic model; and performing a first-time encoding operation on spectral coefficients of the k subbands. In some embodiments of the present disclosure, the quantity k of subbands to be encoded is determined according to the quantity of available bits and the first saturation threshold, and encoding is performed on the k subbands that are selected from all the subbands, instead of on an entire frequency band.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.

Abstract: Embodiments of the present disclosure provide signal encoding and decoding methods and devices. The method includes: determining, a quantity k of subbands to be encoded, where i is a positive number, and k is a positive integer; selecting, according to quantized envelopes of all subbands, k subbands from all the subbands, or selecting k subbands from all subbands according to a psychoacoustic model; and performing a first-time encoding operation on spectral coefficients of the k subbands. In the embodiments of the present disclosure, the quantity k of subbands to be encoded is determined according to the quantity of available bits and the first saturation threshold, and encoding is performed on the k subbands that are selected from all the subbands, instead of on an entire frequency band, which can reduce spectrum holes of a signal obtained through decoding, and therefore, can improve auditory quality of an output signal.

Abstract: The present disclosure provides a speech/audio signal processing method based on wideband switching and a coding apparatus. The method includes: if a first wideband speech/audio signal is a harmonic signal, adjusting a determining condition for determining that a second wideband speech/audio signal is a harmonic signal, to obtain a first determining condition, where the first wideband speech/audio signal is a signal before wideband switching, and the second wideband speech/audio signal is a signal after the wideband switching; and determining, according to the first determining condition, whether the second wideband speech/audio signal is a harmonic signal. In the case of wideband switching, signal types of speech/audio signals remain as consistent as possible before and after the switching, so that continuity of the speech/audio signal decoded by a decoder device is ensured as much as possible, further improving speech communication service quality.

Abstract: An expansion device for a virtual interface is provided. The expansion device is disposed on a mainboard of a server and is configured to acquire control of a plurality of physical resources of the server. The expansion device includes a virtual interface demand control module and a resource management module. The resource management module includes a transmission unit and a physical resource protocol unit. The virtual interface demand control module is configured to acquire control of a plurality of client facilities and arrange a demand timing of each of the client facilities to generate a plurality of interface operation signals. The transmission unit is configured to manage datastreams of the interface operation signals transmitted from the mainboard to the physical resources to decrease central processing unit (CPU) usage on the server. The physical resource protocol unit is configured to control the physical resources according to the interface operation signals.

Abstract: The present disclosure relates to a system for over-expressing a target protein. The system for over-expressing the target protein includes a dihydrofolate reductase (DHFR)-deficient CHO cell, an antifolate analog, a target protein expression plasmid and a CRISPRi expression plasmid. The target protein expression plasmid includes a target protein expression cassette and a DHFR expression cassette. The CRISPRi expression plasmid includes a gRNA cassette and a dCas9 expression cassette. The present disclosure also relates to a method for over-expressing the target protein. The method for over-expressing the target protein includes constructing the target protein expression plasmid, constructing the CRISPRi expression plasmid, establishing a first stable cell line, establishing a second stable cell line and performing a gene amplification.

Abstract: The present disclosure provides a speech/audio signal processing method based on wideband switching and a coding apparatus. The method includes: if a first wideband speech/audio signal is a harmonic signal, adjusting a determining condition for determining that a second wideband speech/audio signal is a harmonic signal, to obtain a first determining condition, where the first wideband speech/audio signal is a signal before wideband switching, and the second wideband speech/audio signal is a signal after the wideband switching; and determining, according to the first determining condition, whether the second wideband speech/audio signal is a harmonic signal. In the case of wideband switching, signal types of speech/audio signals remain as consistent as possible before and after the switching, so that continuity of the speech/audio signal decoded by a decoder device is ensured as much as possible, further improving speech communication service quality.

Abstract: Embodiments of the present application proposes a frequency envelope vector quantization method and apparatus, where the method includes: dividing N frequency envelopes in one frame into N1 vectors; quantizing a first vector in the N1 vectors by using a first codebook, to obtain a code word corresponding to the quantized first vector, where the first codebook is divided into 2B1 portions; determining, according to the code word corresponding to the quantized first vector; determining a second codebook according to the codebook of the ith portion; and quantizing a second vector in the N1 vectors based on the second codebook. In the embodiments of the present application, vector quantization can be performed on frequency envelope vectors by using a codebook with a smaller quantity of bits. Therefore, complexity of vector quantization can be reduced, and an effect of vector quantization can also be ensured.

Abstract: A Cas9 expression plasmid, a genome editing system and a genome editing method for Escherichia coli are provided. The Cas9 expression plasmid includes a tracrRNA sequence, a Cas9 gene and a chloramphenicol resistance gene (CmR). The Cas9 expression plasmid is applied to CRISPR/Cas-coupled ?-red recombineering system for editing genomes of E. coli with high efficiency.

Abstract: Disclosed are a memory management system and a method thereof. The memory management system is configured on a mother board of a server to help a central processing unit of the server to do memory management for a device system. A memory block is connected to the central processing unit of the server and a plurality of host devices are configured in the device system. The system is configured to determine an amount of the host devices configured in the device system; provide a device code to each host device; determine the memory capacity of the memory block; and allocate memory to each host device and accordingly build an allocation table. When the host device requests the central processing unit for accessing data, the central processing unit responds to the host device according to the allocation table, such that the host device uses the memory block to access data.

Abstract: The present disclosure relates to a gene expression regulation system of a Synechococcus elongatus PCC 7942. The gene expression regulation system of the S. elongatus PCC 7942 includes a S. elongatus PCC 7942 cell, a gene expression interference unit and a gene editing unit. The present disclosure also relates to a method for regulating a gene expression of the S. elongatus PCC 7942. The method includes providing the S. elongatus PCC 7942 cell, using the gene editing unit to insert an exogenous gene into the S. elongates PCC 7942 cell, and using the gene expression interference unit to inhibit an expression of a target gene.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).